Academy of Managed Care Pharmacy. Format for Formulary Submissions. Version 2.0. Alexandria, VA, October 2002.

Agema WR, Jukema JW, Zwinderman AH, van der Wall EE. A meta-analysis of the angiotensin-converting enzyme gene polymorphism and restenosis after percutaneous transluminal coronary revascularization: evidence for publication bias. Am Heart J 2002;144(5):760-8.

Agency for Healthcare Research and Quality. Nominations of topics for evidence-based practice centers (EPCs). Federal Register 68(18), January 28, 2003:4213-6.

Anderson, GF, MA Hall, EP Steinberg. Medical technology assessment and practice guidelines: their day in court. Am J Pub Health. 1993;83(3):1635-9.

Anderson JE, Jorenby DE, Scott WJ, Fiore MC. Treating tobacco use and dependence: an evidence-based clinical practice guideline for tobacco cessation. Chest. 2002;121(3):932-41.

Andersson I, Aspegren K, Janzon L, Landberg T, Lindholm K, Linell F, Ljungberg O, Ronstam J, and Sigfusson B. Mammographic Screening and mortality from breast cancer: The Malmö Mammographic Screening Trial. BMJ. 1988; 297(6654):943-8.

Anis AH, Rahman T, Schechter MT. Using pharmacoeconomic analysis to make drug insurance coverage decisions. Pharmacoeconomics. 1998;13(1 Pt 2):119-26.

Anonymous. Panel questions rules on trauma research. The New York Times; April 24, 1994:10.

Arnesen T, Nord E. The value of DALY life: problems with ethics and validity of disability adjusted life years. BMJ. 2000;320:1398.

Asch SM, Sloss EM, Hogan C, Brook RH, Kravitz RL. Measuring underuse and necessary care among elderly Medicare beneficiaries using inpatient and outpatient claims. JAMA. 2000;284:2325-33.

Aspirin Myocardial Infarction Study Research Group. A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. JAMA. 1980;243(7): 661-9.

Auston I, Cahn MA, Selden CR. Literature Search Methods for the Development of Clinical Practice Guidelines. In Clinical Practice Guideline Development: Methodology Perspectives, McCormick KA, Moore SR, Siegel RA, 123-7. Rockville Md: Agency for Health Care Policy and Research, 1994.

Baidas S, Tfayli A, Bhargava P. Thalidomide: an old drug with new clinical applications. Cancer Invest. 2002;20(5-6):835-48.

Balk EM, Bonis PAL, Moskowitz H, et al. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. JAMA. 2002;287:2973-82.

Banta HD, Luce BR. Health Care Technology and Its Assessment: An International Perspective. New York, NY: Oxford University Press; 1993.

Basile J. Hypertension in the elderly: a review of the importance of systolic blood pressure elevation. J Clin Hypertens. 2002;4(2):108-12.

Beebe B, Rosenfeld AB, Collins N. An approach to decisions about coverage of investigational treatments. HMO Practice. 1997;11(2):65-7.

Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA. 2003;289:454-65.

Berger A. High dose chemotherapy offers little benefit in breast cancer. BMJ. 1999 May 29;318(7196):1440.

Berger RL, Celli BR, Meneghetti AL, Bagley PH, et al. Limitations of randomized clinical trials for evaluating emerging operations: the case of lung volume reduction surgery. Ann Thorac Surg. 2001 Aug;72(2):649-57.

Bergner M, Bobbitt RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. Med Care. 1981;19(8):787-805.

Bloom BS, Fendrick AM. The tension between cost containment and the underutilization of effective health services. Int J Technol Assess Health Care. 1996;12:1-8.

Boer GJ, Widner H. Clinical neurotransplantation: core assessment protocol rather than sham surgery as control. Brain Res Bull. 2002;58:547-53.

Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Clin Chem. 2003;49(1):1-6.

Brenner M, Jones B, Daneschvar HL, Triff S. New National Emphysema Treatment Trial paradigm of health care financing administration-sponsored clinical research trials: advances and dilemmas. J Investig Med. 2002;Mar;50(2):95-100.

Briggs A, Clark T, Wolstenholme J, Clarke P. Missing... presumed at random: cost-analysis of incomplete data. Health Econ. 2003;12:377-92.

Brooks H, Bowers R. The assessment of technology. Scientific American. 1970;222(2):13-20.

Brownman GP. Development and aftercare of clinical guidelines: the balance between rigor and pragmatism. JAMA. 2001;286:1509-11.

Bunch WH, Dvonch VM. The value of functional independence measure scores. Am J Phys Med Rehab. 1994;73(1):40-3.

Buring JE, Jonas MA, Hennekens CH. Large and simple randomized trials. In Tools for Evaluating Health Technologies: Five Background Papers. US Congress, Office of Technology Assessment, 1995;167-91. BP-H-142. Washington, DC: US Government Printing Office; 1994.

Busse R, Orvain J, Velasco M, et al. Best practice in undertaking and reporting health technology assessments. Int J Technol Assess Health Care. 2002;18:361-422.

Buxton MJ. Problems in the economic appraisal of new health technology: the evaluation of heart transplants in the UK. In Economic Appraisal of Health Technology in the European Community. Drummond MF, ed. Oxford, England. Oxford Medical Publications, 1987.

Byford S, Palmer S. Common errors and controversies in pharmacoeconomic analyses. Pharmacoeconomics. 1998;13:659-66.

Carlsson P, Jørgensen T. Scanning the horizon for emerging health technologies. Int J Technol Assess Health Care. 1998;14:695-704.

Caro JJ, Caro G, Getsios D, et al. The migraine ACE model: evaluating the impact on time lost and medical resource use. Headache. 2002;40:282-91.

Cebul RD Randomized, controlled trials using the metro firm system. Med Care. 1991;29(suppl. 7):JS9-18.

Center for Evidence-Based Medicine. http://www.cebm.net/ocebm-levels-of-evidence/ - levels. Accessed January 11, 2016.

Chalmers TC, Frank CS, Reitman DR. Minimizing the three stages of publication bias. JAMA. 1990;263(10):1392-5.

Chan L, Topfer L. Health Technology Assessment on the Net: A Guide to Internet Sources of Information. Edmonton, Canada: Alberta Heritage Foundation for Medical Research; June 2003.

Chopra SS. Industry funding of clinical trials: Benefit or bias? JAMA. 2003;290:113.

Choudhdry NK, Stelfox HT, Detsky AS. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. Lancet. 2002;287:612-7.

Chow S, Liu J. Design and Analysis of Clinical Trials. New York, NY: John Wiley & Sons; 1998.

Clarke M. Co-Chair, Cochrane Collaboration Steering Group. Personal communication; July 2, 2003.

Coates & Jarratt, Inc. Course Workbook: Technology Assessment. Anticipating the Consequences of Technological Choices. 1992. Washington, DC.

Coleman RE, Briner WH, Siegel BA. Clinical PET scanning. A short-lived orphan. Int J Technol Assess Health Care. 1992;8(4):610-22.

Combe B. Thalidomide: new indications? Joint Bone Spine. 2001;68:582-7.

Cook DJ, Guyatt GH, Laupacis A, Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest. 1992;102(suppl. 4):305S-11S.

Cooper JD. Paying the piper: the NETT strikes a sour note. National Emphysema Treatment Trial. Ann Thorac Surg. 2001;Aug;72(2):330-3.

Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation. 1990;82:1106-16.

Cutler DM, McClellan M. Is technological change in medicine worth it? Health Aff. 2001;20(5):11-29.

de Bruin AF, de Witte LP, Stevens F, Diederiks JP. Sickness Impact Profile: the state of the art of a generic functional status measure. Soc Sci Med. 1992;35(8):1003-14.

Deeks JJ. Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. BMJ. 2001;323:157-62.

Detsky AS. Using cost-effectiveness analysis to improve the efficiency of allocating funds to clinical trials. Stat Med. 1990;9(1)-2:173-84.

Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbe KA. Incorporating variations in the quality of individual randomized trials into meta-analysis. J Clin Epid. 1992;45(3):255-65.

Deyo RA. Cascade effects of medical technology. Annu Rev Public Health. 2002;23:23-44.

Deyo RA, Psaty BM, Simon G, Wagner EH, Omenn GS. The messenger under attack — intimidation of researchers by special-interest groups. N Engl J Med. 1997;336(16):1176-80.

Dickersin K. How important is publication bias? AIDS Educ Prev. 1997;9(suppl 1):15-21.

Dickersin K, Min YI. Publication bias: the problem that won't go away. Ann N Y Acad Sci. 1993;703,:135-46.

Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ. 1994;309(6964):1286-91.

Djulbegovic B, Lacevic M, Cantor A, et al. The uncertainty principle and industry-sponsored research. Lancet 2000;356:635-8.

Dolan P. Utilitarianism and the measurement and aggregation of quality-adjusted life years. Health Care Anal. 2001;9(1):65-76.

Doll H.A, Black NA, Flood AB, McPherson K. Criterion validation of the Nottingham health profile: patient views of surgery for benign prostatic hypertrophy. Soc Sci Med. 1993;37(1):115-22.

Donabedian A. Quality assessment and assurance: unity of purpose, diversity of means. Inquiry. 1988;25(1):173-92.

Donaldson MS, Sox HC, Jr, eds. Setting Priorities for Health Technology Assessment: A Model Process. Washington, DC: National Academy Press; 1992. Reprinted with permission from the National Academy of Sciences, courtesy of the National Academies Press, Washington, DC.

Dougherty CJ. Ethical perspectives on prospective payment. Hastings Center Report. 1989;19(January/February):5-11.

Douw K, Vondeling H, Eskildensen D, Simpson S. Use of the Internet in scanning the horizon for new and emerging health technologies; a survey involved in horizon scanning. J Med Internet Res.2003;5(1):e6.

Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ. 1996;313:275-83.

Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991;337:867-72.

Eckman MH, Levine HJ, Pauker SG. Decision analytic and cost-effectiveness issues concerning anticoagulant prophylaxis in heart disease. Chest. 1992;102, (suppl. 4):538-49S.

Eddy DM. Selecting technologies for assessment. Int J Technol Assess Health Care.1989;5(4):485-501.

Eddy DM. A Manual for Assessing Health Practices & Designing Practice Policies: The Explicit Approach. Philadelphia, Pa: American College of Physicians, 1992.

Egger M, Davey Smith G, Altman DG, eds. Systematic Reviews in Health Care: Meta-analysis in Context. 2^nded. London, England: BMJ Books; 2001.

Egger M, Davey Smith G, Sterne JA. Uses and abuses of meta-analysis. Clin Med. 2001;1:478-84.

Eisenberg JM. Ten lessons for evidence-based technology assessment. JAMA. 1999;17:1865-9.

Elixhauser A, Halpern M, Schmier J, Luce BR. Health care CBA and CEA from 1991 to 1996: an updated bibliography. Med Care. 1998;36(suppl. 5):MS1-9,MS18-147.

Ellenberg SS. Do large, simple trials have a place in the evaluation of aids therapies? Oncology. 1992;6:55-9,63.

Elwood PC. British studies of aspirin and myocardial infarction. Am J Med.1983;74(6A):50-4.

Elwood PC, Cochrane AL, Burr ML, et al. A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. BMJ. 1974;1(905):436-40.

Elwood PC, Sweetnam PM. Aspirin and secondary mortality after myocardial infarction. Lancet. 1979;2(8156-8157):1313-5.

Enkin M, Keirse MJNC, Renfrew M, Neilson J. A Guide to Effective Care in Pregnancy and Childbirth. Second Edition. New York, NY: Oxford University Press; 1995.

Essink-Bot ML, Stouthard ME, Bonsel GJ. Generalizability of valuations on health states collected with the EuroQol^© questionnaire. Health Economics. 1993;2(3):237-46.

EuroQol^© Group. "EuroQol^© — A new facility for the measurement of health related quality of life. Health Policy.1990;16(3):199-208.

Feeny D, Guyatt G, Tugwell P, eds. Health care Technology: Effectiveness, Efficiency, and Public Policy. Montreal, Canada: Institute for Research on Public Policy; 1986.

ECRI. Health Technology Forecast. Plymouth Meeting, Pa: ECRI; 2002.

Egger M, Juni P, Bartlett C, Holenstein F, Sterne J. How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study. Health Technol Assess. 2003;7(1):1-76.

Ferguson JH. NIH consensus conferences: dissemination and impact. Ann N Y Acad Sci. 1993;703:180-98.

Ferguson JH, Dubinsky M, Kirsch PJ. Court-ordered reimbursement for unproven medical technology. JAMA. 1993;269(16):2116-21.

Ferguson JH, Sherman CR. Panelists' views of 68 NIH consensus conference. Int J Technol Assess Health Care.2001;17(4):542-58.

Ferguson TB Jr, Peterson ED, Coombs LP, et al. Use of continuous quality improvement to increase use of process measures in patients undergoing coronary artery bypass graft surgery: A randomized controlled trial. JAMA. 2003;290:49-56.

Fineberg HV, Bauman R, Sosman M. Computerized cranial tomography: effect on diagnostic and therapeutic plans. JAMA. 1977;238(3):224-30.

Fink A, Kosecoff J, Chassin M, Brook RH. Consensus methods: characteristics and guidelines for use. Am J Pub Health. 1984;74(9):979-83.

Fishman A, Martinez F, Naunheim K, et al; National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med. 2003 May 22;348(21):2059-73.

Fletcher SW. Whither scientific deliberation in health policy recommendations? N Engl J Med. 1997;16:1180-3.

Fletcher SW, Colditz GA. Failure of estrogen plus progestin therapy for prevention. JAMA. 2002;288:366-8.

Forrow L, Taylor WC, Arnold RM. Absolutely relative: how research results are summarized can affect treatment decisions. Am J Med. 1992;92(2):121-94.

Foulds J. Effectiveness of smoking cessation initiatives. Smoking cessation services show good return on investment. BMJ. 2002 Mar 9;324(7337):608-9.

Friedberg M, Saffran B, Stinson TJ, et al. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA. 1999;282:1453-7.

Freiman JA, Chalmers TC, Smith H, Jr., Kuebler RR. The importance of beta, the Type II error and sample size in the design and interpretation of the randomized controlled trial. survey of 71 "negative" trials. N Engl J Med. 1978;299(13):690-4.

Fye WB. The power of clinical trials and guidelines,and the challenge of conflicts of interest. J Am Coll Cardiol. 2003;41:1237-42.

Gallagher M, Hares T, Spencer J, Bradshaw C, Webb I. The nominal group technique: a research tool for general practice? Family Practice. 1993;10(1):76-81.

Gann MJ, Restuccia JD. Total quality management in health care: a view of current and potential research. Med Care Rev. 1994;51(4):467-500.

Gazelle GS, Hunink MG, Kuntz KM, et al. Cost-effectiveness of hepatic metastasectomy in patients with metastatic colorectal carcinoma: a state-transition Monte Carlo decision analysis. Ann Surg. 2003;237:544-55.

Gelijns A, Rosenberg N. The dynamics of technological change in medicine. Health Aff. 1994;13(3):28-46.

Gerard K, Mooney G. QALY league tables: handle with care. Health Economics. 1993;2(1):59-64.

Gibson JL, Martin DK, Singer PA. Priority setting for new technologies in medicine: a transdisciplinary study. BMC Health Serv Res. 2002;2(1):14

Glennie JL, Torrance GW, Baladi JF, et al. The revised Canadian guidelines for the economic evaluation of pharmaceuticals. Pharmacoeconomics. 1999;15(5):459-68.

Gold JA, Zaremski MJ, Lev ER, Shefrin DH. Daubert v. Merrell Dow. The Supreme Court tackles scientific evidence in the courtroom. JAMA. 1993;270(24):2964-7.

Gold MR, Stevenson D, Fryback DG. HALYS and QALYS and DALYS, oh my: similarities and differences in summary measures of population health. Annu Rev Public Health. 2002;23:115-34.

Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.

Goldberg HI, Cummings MA, Steinberg EP, et al. Deliberations on the dissemination of PORT products: translating research findings into improved patient outcomes. Med Care. 1994;32(suppl. 7):JS90-110.

Goodman C, ed. Medical Technology Assessment Directory: A Pilot Reference to Organizations, Assessments, and Information Resources. Washington, DC: Institute of Medicine; 1988.

Goodman C. It's time to rethink health care technology assessment. Int J Technol Assess Health Care. 1992;8(2):335-58.

Goodman C. Literature Searching and Evidence Interpretation for Assessing Health Care Practices. Stockholm, Sweden: Swedish Council on Technology Assessment in Health Care; 1993.

Goodman C. The moving target problem and other lessons from percutaneous transluminal coronary angioplasty. In: A Szczepura, Kankaanpää J. Assessment of Health Care Technologies: Case Studies, Key Concepts and Strategic Issues. New York, NY: John Wiley & Sons; 1996:29-65.

Goodman C, Baratz SR, eds. Improving Consensus Development for Health Technology Assessment: An International Perspective. Washington, DC: National Academy Press; 1990.

Goodman C, Snider G, Flynn K. Health Care Technology Assessment in VA. Boston, Mass: Management Decision and Research Center. Washington, DC: Health Services Research and Development Service; 1996.

Goodman CS. Healthcare technology assessment: methods, framework, and role in policy making. Am J Manag Care. 1998;4:SP200-14.

Goodman CS. Technology assessment in healthcare: a means for pursuing the goals of biomedical engineering. Med Biolog Eng Comput. 1993;31(1):HTA3-10.

Gøtsche PC. Multiple publication of reports of drug trials. Eur J Clin Pharmacol. 1989;36:429-32.

Graves N, Walker D, Raine R, et al. Cost data for individual patients included in clinical studies: no amount of statistical analysis can compensate for inadequate costing methods. Health Economics. 2002;11:735-9.

Gregorian RS, Golden KA, Bahce A, Goodman C, Kwong WJ, Khan ZM. Antidepressant-induced sexual dysfunction. Ann Pharmacother. 2002;36:1577-89.

Grimes DA. Technology follies: the uncritical acceptance of medical innovation. JAMA. 1993;269(23):3030-3.

Guyatt GH, Haynes RB, Jaeschke RZ, et al. Users' guide to the medical literature, XXV: Evidence-based medicine: principles for applying the users' guides to patient care. Evidence-Based Medicine Working Group. JAMA. 2000;284:1290-6.

Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ. 2001;323:334-6.

Harper G, Townsend J, Buxton M. The preliminary economic evaluation of the health technologies for the prioritization of health technology assessments. Int J Technol Assess Health Care. 1998;14:652-62.

Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force. A review of the process. Am J Prev Med. 2001;20(3S):21-35.

Hasselblad V, Hedges LV. Meta-analysis of screening and diagnostic tests. Psychol Bull. 1995;117(1): 167-78.

Hayward RSA., Wilson MC, Tunis SR, Bass EB, Guyatt G. Users' guides to the medical literature. VIII. How to use clinical practice guidelines. A. Are the recommendations valid? JAMA. 1995;274(7):570-4.

Heitman E. Ethical issues in technology assessment. Conceptual categories and procedural considerations. Int J Technol Assess Health Care. 1998;14(3):544-66.

Henry D, Lopert R. Pharmacoeconomics and policy decisions: The Australian health care system. Clin Ther. 1999;21:909-15.

Henshall C, Koch P, von Below GC, Boer A, et al. Health technology assessment in policy and practice. Int J Technol Assess Health Care. 2002;18(2):447-55.

Hilborne LH, Leape LL, Kahan JP, Park RE, Kamberg CJ, Brook RH. Percutaneous Transluminal Coronary Angioplasty: A Literature Review of Ratings of Appropriateness and Necessity. Santa Monica, Ca: RAND; 1991.

Hill SR, Mitchell AS, Henry DA. Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA. 2000;283(16):2116-21.

Hjelmgren J, Berggren F, Andersson F. Health economic guidelines--similarities, differences and some implications. Value Health. 2001;4(3):225-50.

Hoffman B. Is there a technological imperative in health care? Int J Technol Assess Health Care. 2002;18(3):675-89.

Hogness JR,Van Antwerp M. The Artificial Heart: Prototypes, Policies, and Patients. Washington, DC: National Academy Press; 1991. Reprinted with permission from the National Academy of Sciences, courtesy of the National Academies Press, Washington, DC.

Horng S, Miller FG. Ethical framework for the use of sham procedures in clinical trials. Crit Care Med. 2003;31(suppl. 3):S126-30.

Hunt DL, Jaeschke R, McKibbon KA. Users' guides to the medical literature: XXI. Using electronic health information resources in evidence-based practice. Evidence-Based Medicine Working Group. JAMA 2000;283(14):1875-9.

International Network of Agencies for Health Technology Assessment (INAHTA). http://www.inahta.org/. Accessed June 1, 2003.

Institute for the Future. Health & Health Care 2010. The Forecast, The challenge. San Francisco, Ca: Jossey-Bass Publishers; 2000.

Institute of Medicine. Assessing Medical Technologies. Washington, DC: National Academy Press; 1985.

Institute of Medicine. Assessment of Diagnostic Technology in Health Care. Rationale,Methods, Problems, and Directions. Washington, DC: National Academy Press; 1989. Reprinted with permission from the National Academy of Sciences, courtesy of the National Academies Press, Washington, DC.

Institute of Medicine. Consensus Development at the NIH: Improving the Program. Washington, DC: National Academy Press; 1990.

Institute of Medicine, Committee on Quality of Health Care in America. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: National Academy Press; 2001.

International Committee of Medical Journal Writers. Conflict of interest. Lancet. 1993;341(8847):742-3.

International Committee of Medical Journal Writers. Uniform requirements for manuscripts submitted to biomedical journals. N Engl J Med. 1997;336:309-15.

Ioannidis JPA. Effects of statistical significance of results on the time to completion and publication of randomized efficacy trials. JAMA. 1998;279:281-6.

Irwig L, Tosteson AN, Gatsonis C, Lau J, Colditz G, Chalmers TC, Mosteller F. Guidelines for meta-analyses evaluating diagnostic tests. Ann Intern Med. 1994;120(8):667-76.

Jadad AR, Moore RA, Carrol D, et al. Asssessing the quality of reports of randomized clinical trials: Is blinding necessary? Controlled Clin Trials. 1996;17:1-12.

Jairath N, Weinstein J. The Delphi methodology (part two): a useful administrative approach. Can J Nurs Admin. 1994;7(4):7-20.

Jenkinson C, Fitzpatrick R, Argyle M. The Nottingham Health Profile: an analysis of its sensitivity to differentiating illness groups. Soc Sci Med. 1988;27(12):1411-4.

Johannesson M, Pliskin JS, Weinstein MC. Are healthy-years equivalents an improvement over quality-adjusted life years? Med Dec Making. 1993;13(4):281-6.

Jorenby DE, Leischow SJ, Nides MA, Rennard SI, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999 Mar 4;340(9):685-91.

Juni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA. 1999;182:1054-60.

Kaden RJ, Vaul JH, Palazola PA. Negotiating payment for new technology purchases. Healthc Financ Manage. 2002;56(12):44-8.

Kahan JP, Bernstein SJ, Leape LL, Hilborne LH, Park RE, Parker L, Kamberg CJ, Brook RH. Measuring the necessity of medical procedures. Med Care. 1994;32(4):357-65.

Kahan JP, Kanouse DE, Winkler JD. Stylistic variations in National Institutes of Health consensus statements, 1979-1983. Int J Technol Assess Health Care. 1988;4(2):289-304.

Kaplan RM, Anderson JP. A general health policy model: update and applications. Health Services Research. 1988;23,:203-35.

Kaplan RM, Anderson JP, Wu AW, Mathews WC, Kozin F, Orenstein D. The Quality of Well-being Scale: applications in AIDS, cystic fibrosis, and arthritis. Med Care. 1989;27(suppl. 3):S27-43.

Kassirer JP, Angell M. Financial conflicts of interest in biomedical research. N Engl J Med. 1993;329:570-1.

Kassirer JP, Angell M. The journal's policy on cost-effectiveness analyses. N Engl J Med. 1994;331:669-70.

Katz S, Downs TD, Cash HR, Grotz RC. Progress in the development of the index of ADL. Gerontologist. 1970;10(part I):20-30.

Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care. 1989;27(suppl. 3):S178-189.

Kim S, Losina E, Solomon DH, Wright J, Katz JN. Effectiveness of clinical pathways for total knee and total hip arthroplasty: literature review. J Arthroplasty. 2003;18(1):69-74.

Kleinman LC, Kosecoff J, Dubois RW, Brook RH. The medical appropriateness of tympanostomy tubes proposed for children younger than 16 years in the United States. JAMA. 1994;271(16):1250-5.

Kwan J, Sandercock P. In-hospital care pathways for stroke: a Cochrane systematic review. Stroke. 2003;34(2):587-8.

Laird NM, Mosteller F. Some statistical methods for combining experimental results. Int J Technol Assess Health Care. 1990;6(1):5-30.

Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348:2175-85.

Lara ME, Goodman C, eds. National Priorities for the Assessment of Clinical Conditions and Medical Technologies. Washington, DC: National Academy Press; 1990.

Lau J, Antman EM, Jiminez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med. 1992;327(4):248-54. Copyright © 1992 Massachusetts Medical Society. All rights reserved.

Lazaridis EN, Rudberg MA, Furner MA, Cassel CK. Do activities of daily living have a hierarchical structure? An analysis using the longitudinal study of aging. J Gerontol. 1994;49(2):M47-51.

The Lewin Group. Outlook for Medical Technology Innovation. Report 2: The Medicare Payment Process and Patient Access to Technology. Washington, DC: AdvaMed; 2000.

The Lewin Group. Outlook for Medical Technology Innovation. Report 4: The Impact of Regulation and Market Dynamics on Innovation. Washington, DC: AdvaMed; 2001.

The Lewin Group. The Clinical Review Process Conducted by Group Purchasing Organizations and Health Systems. Prepared for the Health Industry Group Purchasing Association, April 2002.

Linacre JM, Heinemann AW, Wright BD, Granger CV, Hamilton BB. The structure and stability of the Functional Independence Measure. Arch Phys Med Rehab. 1994;75(2):127-32.

Littenberg B, Moses LE. Estimating diagnostic accuracy from multiple conflicting reports: a new meta-analytic method. Med Dec Making. 1993;13(4):313-21.

Lo B, Wolf LE, Berkeley A. Conflict-of-interest policies for investigators in clinical trials. N Engl J Med. 2000;343(22):1616-20.

Lohr KN, ed. Institute of Medicine. Medicare: a Strategy for Quality Assurance. Volume I. Washington, DC. National Academy Press; 1990.

Lohr KN, Rettig RA, eds. Quality of Care and Technology Assessment. Report of a Forum of the Council on Health Care Technology. Washington, DC: National Academy Press; 1988.

Lyles A. Direct marketing of pharmaceuticals to consumers. Annu Rev Public Health. 2002;23:73-91.

MacLean CH, Morton SC, Ofman JJ, Roth EA, Shekelle PG. How useful are unpublished data from the Food and Drug Administration in meta-analysis? J Clin Epidemiol. 2003 Jan;56(1):44-51.

Mason JM. Cost-per QALY league tables: Their roles in pharmacoeconomic analysis. Pharmacoeconomics. 1994;5:472-81.

Massa T. An industry perspective: challenges in the development and regulation of drug-device combination products. In Hanna K, Manning FJ, Bouxsein P, Pope A, eds. Innovation and Invention in Medical Devices. Workshop Summary. Institute of Medicine. Washington, DC: National Academy Press; 2002:16-20.

Maynard A. Developing the health care market. Econ J. 1991;101:1277-86.

McDonald IG. Quality assurance and technology assessment: pieces of a larger puzzle. J Qual Clin Pract. 2000;20(2-3):87-94.

McGivney WT. Proposal for assuring technology competency and leadership in medicine. JNCI. 1992;84(10):742-5.

McGlynn EA, Asch SM, Adams J, Keesey J, Hicks J, DeCristofaro A, Kerr EA. The quality of health care delivered to adults in the United States. N Engl J Med. 2003 Jun 26;348(26):2635-45.

McGlynn EA, Kosecoff J, Brook RH. Format and conduct of consensus development conferences. Multi-nation comparison. Int J Technol Assess Health Care. 1990;6(3):450-69.

McHorney CA, Ware JE, Jr, Lu JF, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 1994;32(1):40-66.

McKinlay JB. From "promising report" to "standard procedure": seven stages in the career of a medical innovation. Milbank Memorial Fund Quarterly. 1981;59(3):374-411.

McNeil BJ. Shattuck Lecture −Hidden barriers to improvement in the quality of care. N Engl J Med. 2001;345:1612-20.

Medical Technology Leadership Forum. MTLF Summit: Conditional Coverage of Investigational Technologies. Prepared by The Lewin Group. Washington, DC; October 1999.

Medicare Payment Advisory Commission. Accounting for new technology in hospital prospective payment systems. In Report to the Congress: Medicare Payment Policy. Washington, DC: Medicare Payment Advisory Commission; 2001;33-45.

Meenan RF, Mason JH, Anderson JJ, Guccione AA, Kazis LE. AIMS2. The content and properties of revised and expanded arthritis impact measurement scales health status questionnaire. Arthritis and Rheumatism. 1992;35(1):1-10.

Mehrez A, Gafni A. Healthy-years equivalents versus quality-adjusted life years: In pursuit of progress. Med Dec Making. 1993;13(4):287-92.

Mello MM, Brennan TA. The controversy over high-dose chemotherapy with autologous bone marrow transplant for breast cancer. Health Aff. 2001;20(5):101-17.

Mendelson DN, Goodman CS, Ahn R, Rubin RJ. Outcomes and effectiveness research in the private sector and role of the Agency for Health Care Policy and Research. Health Aff. 1998;17(5):75-90.

Merigan TC. You can teach an old dog new tricks: how AIDS trials are pioneering new strategies. N Engl J Med 323. 1990(19):1341-3.

Mills RM, Jr, M. Kalan J. Developing a rational management strategy for angina pectoris after coronary bypass surgery: a clinical decision analysis. Clin Cardiol. 1991;14(3):191-7.

Miranda B, Matesanz R. International issues in transplantation. Setting the scene and flagging the most urgent and controversial issues. Ann N Y Acad Sci. 1998;862:129-43.

Mittman BS, Siu AL. Changing provider behavior: applying research on outcomes and effectiveness in health care. In Improving Health Policy and Management: Nine Critical Research Issues for the 1990s. Shortell SM, Reinhardt UE eds. 195-226. Ann Arbor, Mich: Health Administration Press; 1992.

Mittman BS, Tonesk X, Jacobson PD. Implementing clinical practice guidelines: social influence strategies and practitioner behaviour change. Qual Rev Bull 1992;18:413-21.

Moher D, Cook DJ, Eastwood S, Olkin I, et al. Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet. 1999;354:1896-900.

Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in nmeta-analyses? Lancet 1998;352:609-13.

Moher D, Dulberg CS, Wells GA. Statistical power, sample size, and their reporting in randomized controlled trials. JAMA. 1994;272:122-4.

Moher D, Jadad AR, Tugwell R. Assessing the quality of randomized controlled trials. Current issues and future directions. Int J Technol Assess Health Care. 1996;12(2):195-208.

Moher D, Schulz KF, Altman D, et al. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA. 2001;285(15):1987-91.

Moseley JB, O'Malley K, Petersen NJ, et al. A controlled trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med. 2002;347:81-8.

Mowatt G, Bower DJ, Brebner JA, Cairns JA, Grant AM, McKee L. When and how to assess fast-changing technologies: a comparative study of medical applications of four generic technologies. Health Technology Assessment. 1997;1(14).

Murphy MK, Black NA, Lamping DL, et al. Consensus development methods, and their use in clinical guideline development. Health Technol Assessment. 1998;2(3):i-iv, 1-88.

National Academy of Engineering, Committee on Public Engineering policy. A Study of Technology Assessment. Washington, DC: US Government Printing Office; 1969.

National Committee for Quality Assurance. The State of Health Care Quality: 2003. Washington, DC, 2003.

National Institute for Clinical Evidence. Guidance for Manufacturers and Sponsors. Technology Appraisals Process Series No. 5. London, June 2001.

National Library of Medicine, National Information Center on Health Services Research & Health Care Technology. Etext on Health Technology Assessment (HTA) Information Resources. //www.nlm.nih.gov/archive//20060905/nichsr/ehta/ehta.html . Accessed June 1, 2003.

National Research Council, Committee on the Life Sciences and Social Policy. Assessing Biomedical Technologies: An Inquiry into the Nature of the Process. Washington, DC: National Academy of Sciences; 1975.

Neuhauser D, Lewicki AM. What do we gain from the sixth stool guaiac? N Engl J Med. 1975;293:226-8. Copyright © 1975 Massachusetts Medical Society. All rights reserved.

Neumann PJ, Claxton K, Weinstein MC. The FDA's regulation of health economic information. Health Aff. 2000;19(5):129-37.

Newcomer LN. Defining experimental therapy – a third party payer's dilemma. N Engl J Med 323. 1990(24):1702-4.

Newhouse JP. Medical care costs: how much welfare loss? J Econ Perspect. 1992;6(3):3-21.

NHS Centre for Reviews and Dissemination. Undertaking Systematic Reviews of Research on Effectiveness. CRD Guidelines for Those Carrying Out or Commissioning Reviews. CRD Report 4. University of York, UK; 1996.

Nixon J, Stoykova B, Glanville J, Christie J, Drummond M, Kleijnen J. The U.K. NHS Economic Evaluation Database. Economic issues in evaluations of health technology. Int J Technol Assess Health Care. 2000;731-42.

Nord E. The QALY – a measure of social value rather than individual utility? Health Econ. 1994;3(2):89-93.

Normand SL. Meta-analysis: formulating, evaluating, combining, and reporting. Stat Med. 1999;18:321-59.

O'Brien BJ, Buxton MJ, Patterson, DL. Relationship between functional status and health-related quality-of-life after myocardial infarction. Med Care. 1993;31(10):950-5.

Olson CM. Consensus statements: applying structure. JAMA. 1995;273(1):72-3.

Olson O, Gøtzsche PC. Cochrane review on screening for breast cancer with mammography. Lancet. 2001;358:1340-2.

Oxman AD, Sackett DL, Guyatt GH. Users' guides to the medical literature. I. How to get started. JAMA. 1993;270(17):2093-5.

Passamani E. Clinical trials: are they ethical? N Engl J Med. 1991;324(22):1589-92.

Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Mel Care. 1989;27(suppl. 3):S217-32.

Patrick DL, Starks HE, Cain KC, Uhlmann RF, Pearlman RA. Measuring preferences for health states

worse than death. Med Dec Making. 1994;14(1):9-18.

Pauker SG, Kassirer, JP. Decision analysis. N Engl J Med. 1987;316(5):250-8.

Petitti DB. Approaches to heterogeneity in meta-analysis. Stat Med. 2001;20:3625-33.

Peto R, Collins R, Gray R. Large-scale randomized evidence: large, simple trials and overviews of trials. Ann N Y Acad Sci. 1993;703:314-40.

Phelps CE, Mooney C. Correction and update on 'priority setting in medical technology assessment.'Medical Care. 1992;30(8):744-51.

Phelps CE, Mushlin AI. On the (near) equivalence of cost-effectiveness and cost-benefit analyses. Int J Technol Assess Health Care. 1991;7:12-21.

Phillips WR. Clinical policies: making conflicts of interest explicit. Task force on clinical policies for patient care. American Academy of Family Physicians. JAMA. 1994;272(19):1479.

Pilnick A, Dingwall R, Starkey K. Disease management: definitions, difficulties and future directions.

Bull World Health Organ.2001;79(8):755-63.

Poe NR, Griffiths RI. Clinical-economic Trials. In Tools for Evaluating Health Technologies: Five Background Papers. US Congress, Office of Technology Assessment, BP-H-142, 125-49. Washington, DC: US Government Printing Office; 1995.

Ramsey SD, Berry K, Etzioni R, Kaplan RM, Sullivan SD, Wood DE; National Emphysema Treatment Trial Research Group. Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema. N Engl J Med. 2003;348(21):2092-102.

Reiser SJ. Criteria for standard versus experimental therapy. Health Aff. 1994;13(3):127-36.

Relman AS. Financial incentives in clinical investigation. N Engl J Med. 1989;320:933-34.

Rettig RA. Health Care in Transition: Technology Assessment in the Private Sector. Santa Monica, Ca: RAND; 1997.

Rettig RA, Levinsky NG, eds. Kidney Failure and the Federal Government. Washington, DC: National Academy Press; 1991.

Reuzel RP, van der Wilt GJ, ten Have HA, de Vries Robbe PF. Interactive technology assessment and wide reflective equilibrium. J Med Philos. 2001;26(3):245-61.

Richardson P, Hideshima T, Anderson K. Thalidomide: emerging role in cancer medicine. Annu Rev Med. 2002;53;629-57.

Rothenberg, Carbone DP, Johnson DH. Improving the evaluation of new cancer treatments: challenges and opportunities. Nat Rev Cancer. 2003;3:303-9.

Rothman KJ, Michels KB. The continuing unethical use of placebo controls. N Engl J Med. 1994;331:394-7.

Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-33.

RTI International-University of North Carolina Evidence-based Practice Center. Systems to Rate the Strength of Scientific Evidence. Evidence Report/Technology Assessment Number 47. AHRQ Publication No. 02-E016, Rockville, Md: Agency for Healthcare Research and Quality, April 2002.

Sassi, F. Setting priorities for the evaluation of health interventions: when theory does not meet practice. Health Policy. 2003;63:141-54.

Sackett DL, Richardson WS, Rosenberg W, Haynes RB. Evidence-Based Medicine. New York, NY: Churchill Livingstone, 1997.

Sadock J, Tolman ED. Capital equipment budgeting: changing an art to a science. J Healthc Resour Manag. 1997;15(8):16-21.

Schauffler HH, Barker DC, Orleans CT. Medicaid coverage for tobacco-dependence treatments. Health Aff. 2001;20(1):298-303.

Schulz KF, Chalmers I, Hayes RJ, Altman DG Empirical evidence of bias: dimensions of methodological quality associated with effects in controlled trials. JAMA. 1995;273:408-12.

Schwappach DL. Resource allocation, social values and the QALY: a review of the debate and empirical evidence. Health Expect. 2002;5(3):210-22.

Sharf BF. Out of the closet and into the legislature: breast cancer stories. Health Aff. 2001;20(1):213-8.

Sheingold, SH. Technology assessment, coverage decisions, and conflict: the role of guidelines. Am J Manag Care. 1998;4:SP117-25.

Shekelle P, Eccles MP, Grimshaw JM, Woolf SH. When should clinical guidelines be updated? BMJ. 2001;323:155-7.

Shekelle PG, Ortiz E, Rhodes S, Morton SC, Eccles MP, Grimshaw JM, Woolf SH. Validity of the Agency for Healthcare Research and Quality clinical practice guidelines: how quickly do guidelines become outdated? JAMA. 2001;286:1461-7.

Singer SJ, Bergthold LA. Prospects for improved decision making about medical necessity. Health Aff. 2001;20(1):200-6.

Soto J. Health economic evaluations using decision analytic modeling. Principles and practices--utilization of a checklist to their development and appraisal. Int J Technol Assess Health Care. 2002;18:94-111.

Soumerai SB, Lipton HL. Computer-based drug-utilization review – risk, benefit, or boondoggle? N Engl J Med. 1995;332:1641-5.

Spilker B. Guide to Clinical Trials. New York, NY: Raven Press, 1991.

Spilker B. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia, Pa: Lippincott Williams & Wilkins, 1995.

Steinberg EP. Cost-effectiveness analyses. N Engl J Med. 1995;332:123.

Steinberg EP, Tielsch JM, Schein OD, Javitt JC, et al. The VF-14. An index of functional impairment in patients with cataract. Arch Ophthal. 1994;112(5):630-8.

Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ. 2001;323:101-5.

Stevens A, Robert G, Packer C. Early warning of new health care technologies in the United Kingdom. Int J Technol Assess Health Care. 1998;14:680-6.

Stone GW, Teirstein PS, Rubenstein R, et al. A prospective, multicenter, randomized trial of percutaneous transmyocardial laser revascularization in patients with nonrecanalizable chronic total occlusions. J Am Coll Cardiol. 2002;39:1581-7.

Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology. A proposal for reporting. JAMA. 2000;283:2008-12.

Stryer D, Bero LA. Characteristics of materials distributed by drug companies. An evaluation of appropriateness. J Gen Intern Med. 1996;11(10):575-83.

Suarez-Almazor ME, Belseck E, Homik J, et al. Identifying clinical trials in the medical literature with electronic databases: MEDLINE alone is not enough. Control Clin Trials. 2000;21:476-87.

Taylor KS. Hospital tech assessment teams field requests − and politics. Hosp Health Netw. 1994;68(16):58.

Taylor RS, Hutton J, Culyer AJ. Developing the revised NICE appraisal technical guidance to manufacturers and sponsors: opportunity or threat? Pharmacoeconomics. 2002;20:1031-8.

Thacker SB. Meta-analysis: A quantitative approach to research integration. JAMA. 1988; 259(11):1685-9.

Thamer M, Ray NF, Henderson SC, et al. Influence of the NIH Consensus Conference on Helicobacter pylori on physician prescribing among a Medicaid population. Med Care. 1998;36(5):646-60.

The Coronary Drug Project Research Group. Aspirin in coronary heart disease. J Chron Dis. 1976;29(10):625-42.

The Ischemic Optic Neuropathy Decompression Trial Research Group. Optic nerve decompression surgery for nonarteritic anterior ischemic optic neuropathy (NAION) is not effective and may be harmful. JAMA. 1995;273(8):625-32.

The Nuremberg Code, from Trials of War Criminals Before the Nuremberg Military Tribunals under Control Council Law. 2(10):181-82. Washington, DC: US Government Printing Office; 1949.

The Persantine-Aspirin Reinfarction Study Research Group. Persantine and aspirin in coronary heart disease. Circulation. 1980;62(3):449-61.

Thornbury JR, Fryback DG. Technology assessment – An American view. Eur J Radiol. 1992;14(2):147-56.

Thornquist MD, Urban N, Tseng A, Edelstein C, Lund B, Omenn GS. Research cost analyses to aid in decision making in the conduct of a large prevention trial, CARET. Carotene and Retinol Efficacy Trial. Control Clin Trials. 1993;14(4):325-39.

Thornton JG, Lilford RJ, Johnston N. Decision analysis in medicine. BMJ. 1992;304(6834):1099-103.

Tom E, Schulman KA. Mathematical models in decision analysis. Infect Control Hosp Epidemiol. 1997 Jan;18(1):65-73.

Topfer L, Parado A, Menon D, et al. Comparison of literature searches on quality and costs for health technology assessment using MEDLINE and EMBASE databases. Int J Technol Assess Health Care. 1999;15(2):297-303.

Torrance GW, Feeny D. Utilities and quality-adjusted life years. Int J Technol Assess Health Care. 1989;5(4):559-75.

Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003;290(12):1624-32.

Tymstra T. The imperative character of medical technology and the meaning of 'anticipated decision regret.' Int J Technol Assess Health Care. 1989;5:207-13.

Ubel PA, Nord E, Gold M, et al. Improving value measurement in cost-effectiveness analysis. Med Care. 2000;38:892-901.

UK National Health Service R&D Health Technology Assessment Programme, 2003. http://www.ncchta.org/about/index.shtml. Accessed June 1, 2003.

University HealthSystem Consortium. Clinical Practice Advancement Center. Technology Report: Implementation of Hospital-Based Technology Assessment. Oak Brook Ill.: UHC Services Corporation; 1996.

US Congress, House of Representatives. Committee on Science and Astronautics. Technology Assessment. Statement of Emilio Q. Daddario, Chairman, Subcommittee on Science Research and Development. 90th Cong., 1st sess., Washington, DC; 1967.

US Congress, Office of Technology Assessment. Technology Assessment in Business and Government. Summary and Analysis. Washington, DC: US Government Printing Office; 1977.

US Congress, Office of Technology Assessment. Strategies for Medical Technology Assessment. Washington, DC: US Government Printing Office; 1983.

US Congress, Office of Technology Assessment. Protecting Privacy in Computerized Medical Information. Washington, DC: US Government Printing Office; 1994.

US Department of Health and Human Services, Agency for Health Care Policy and Research. Extracranial-Intracranial Bypass to Reduce the Risk of Ischemic Stroke. Health Technology Assessment Reports. No. 6. Rockville, Md; 1990.

US Department of Health and Human Services, Agency for Health Care Policy and Research. Intermittent Positive Pressure Breathing: Old Technologies Rarely Die. Rockville, Md; 1993.

US Preventive Services Task Force. Screening for prostate cancer: recommendations and rationale. Ann Intern Med. 2002;137:915-6.

van den Broek SA, van Veldhuisen DJ, de Graeff PA, et al. Comparison between New York Heart Association classification and peak oxygen consumption in the assessment of functional status and prognosis in patients with mild to moderate chronic congestive heart failure. Am J Cardiol. 1992;70(3):359-63.

Van der Wilt GJ, Reuzel R, Banta HD. The ethics of assessing health technologies. Theor Med Bioeth. 2000;21(1):103-15.

van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med. 2002;21:589-624.

Varmus H, Satcher D. Ethical complexities of conducting research in developing countries. N Engl J Med. 1997;337(14):1003-5.

Wakefield DS, Wakefield BJ. Overcoming barriers to implementation of TQM/CQI in hospitals: myths and realities. QRB. Quality Review Bulletin. 1993;19(3):83-8.

Ware JE Jr., Sherbourne CD. The MOS 36-item Short Form Health Survey (SF-36): I. conceptual framework and item selection. Med Care. 1992;30(6):473-83.

Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices – Modeling Studies. Value Health. 2003;6(1):9-17.

Willke RJ, Glick HA, Polsky D, Schulman K. Estimating country-specific cost-effectiveness from multinational clinical trials. Health Economics. 1998;7:481-93.

Wood DE, DeCamp MM. The National Emphysema Treatment Trial: a paradigm for future surgical trials. Ann Thorac Surg. 2001;72(2):327-9.

Woolacott NF, Jones L, Forbes CA, et al. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. Health Technol Assess. 2002;6(16):1-245.

World Development Report 1993: Investing in Health. The World Bank. New York, NY: Oxford University Press, 1993.

Yoshida EM. Selecting candidates for liver transplantation: a medical ethics perspective on the microallocation of a scarce and rationed resource. Can J Gastroenterol. 1998;12(3):209-15.

Yusuf S, Held P, Teo KK, Toretsky ER. Selection of patients for randomized controlled trials: implications of wide or narrow eligibility criteria. Stat Med. 1990;9(1-2):73-83.

Page 1 of 1